https://www.selleckchem.com/pr....oducts/ap-3-a4-enobl
05). After treatment, the concentrations in the two groups were significantly lower than those before treatment (P 0.05), and the concentrations in the observation group were significantly lower than those in the control group (P 0.05). There was no significant difference in the 3-year OS between the observation and control groups (P 0.05). Nimotuzumab combined with cisplatin could improve the conditions of patients with nasopharyngeal carcinoma. After treatment, the expression of VEGF and MMP-2 decreased signifi
Curtir
Comentario
Compartilhar
